Diagnosing Alzheimer’s disease involves a combination of cognitive screening, blood work, brain imaging, and sometimes spinal fluid analysis. There is no single test that confirms the diagnosis on its own. Instead, doctors build a case by layering results from several types of evaluations, ruling out other causes of memory loss along the way.
The process typically starts with a primary care doctor, who may then refer you to a specialist: a neurologist, geriatrician, geriatric psychiatrist, or neuropsychologist. Many people end up at a memory clinic where a team of specialists works together. Follow-up visits every six to twelve months help track how symptoms change over time, which is itself an important diagnostic signal.
Cognitive and Memory Screening
The first step is usually a structured test of thinking and memory. The most widely used screening tool is the Montreal Cognitive Assessment (MoCA), a 30-point test that checks short-term recall, attention, language, visual-spatial ability, and orientation to time and place. A score of 26 or above is considered normal, and one point is added for people with 12 or fewer years of education to account for that difference. The test takes about 10 to 15 minutes.
These screenings are not pass-or-fail exams. A low score doesn’t automatically mean Alzheimer’s, and a normal score doesn’t rule it out, especially in highly educated people who can compensate for early deficits. Doctors also ask detailed questions of both the patient and a close family member or friend, covering changes in behavior, personality, ability to manage daily tasks like cooking or paying bills, and use of medications. That informant interview often reveals patterns the person themselves may not notice or report.
Blood Tests to Rule Out Other Causes
Several treatable conditions can mimic or worsen dementia symptoms. Before pursuing Alzheimer’s-specific testing, doctors order routine blood work to check for vitamin B12 deficiency, thyroid dysfunction, and in some cases, infections like HIV or syphilis that are known to cause cognitive decline. A psychiatric evaluation may also be part of this stage, since depression in older adults can look remarkably similar to early dementia.
These aren’t just formalities. Thyroid problems and B12 deficiency are common in older adults and genuinely reversible. Catching them early can save someone from an unnecessary Alzheimer’s diagnosis or reveal that a treatable condition is making actual Alzheimer’s symptoms worse than they would otherwise be.
Blood Tests for Alzheimer’s Itself
A newer category of blood tests can now detect proteins directly linked to Alzheimer’s pathology. The most promising measures a form of tau protein called p-tau217. In a validation study at Mayo Clinic outpatient memory clinics, this blood test confirmed an Alzheimer’s diagnosis with 95% sensitivity and 82% specificity. That means it correctly identified 95 out of 100 people who truly had the disease, while producing some false positives in people who did not.
The 2024 diagnostic criteria from the National Institute on Aging and the Alzheimer’s Association formally incorporated plasma (blood-based) biomarkers into their framework for diagnosing and staging the disease. This is a significant shift. Previously, confirming Alzheimer’s biology required either a spinal tap or an expensive PET scan. Blood tests are making biological confirmation more accessible, though they are currently intended for people who already have symptoms, not for screening the general population.
Brain Imaging
Brain scans serve two purposes: they can reveal patterns of damage consistent with Alzheimer’s, and they can rule out other explanations like strokes, tumors, or fluid buildup in the brain.
An MRI is the most common imaging test. In Alzheimer’s, it typically shows shrinkage in the hippocampus (the brain’s memory center), the amygdala, and areas of the temporal and parietal lobes, while regions responsible for basic movement and sensation remain relatively intact. This specific pattern of atrophy helps distinguish Alzheimer’s from other forms of dementia.
PET scans go a step further by measuring brain activity or detecting specific proteins. One type uses a glucose tracer to map which parts of the brain are less active than expected. Others use newer tracers that bind directly to amyloid plaques or tau tangles, the two hallmark proteins of the disease. An amyloid PET scan showing abnormal results will reveal a loss of contrast between white and gray matter, indicating widespread plaque deposits. Tau PET scans can show where tangles have accumulated, which correlates closely with where symptoms are most severe.
Not everyone needs a PET scan. They are expensive, not always covered by insurance, and often reserved for cases where the diagnosis is unclear after other testing.
Spinal Fluid Analysis
A lumbar puncture (spinal tap) collects cerebrospinal fluid, which bathes the brain and spinal cord and contains measurable levels of Alzheimer’s-related proteins. Doctors look at two key proteins: amyloid-beta 42, which drops in the spinal fluid when it’s being trapped in brain plaques, and phosphorylated tau, which rises as tangles form. The ratio between these two proteins is particularly telling. In one large study, the ratio of phosphorylated tau to amyloid-beta 42 had the highest diagnostic accuracy of any single spinal fluid measurement.
A spinal tap sounds intimidating, but the procedure itself takes about 20 to 30 minutes and is done with local anesthesia. The most common side effect is a headache lasting a day or two. This test is especially useful when imaging results are inconclusive or when doctors need biological confirmation before starting certain treatments.
Neurological Exam
A standard neurological exam checks balance, reflexes, coordination, sensory function, and muscle tone. This isn’t primarily about detecting Alzheimer’s. It helps identify other conditions that could explain or contribute to cognitive decline, such as Parkinson’s disease, prior strokes, or other movement disorders. Some of these conditions are treatable, and identifying them changes the management plan significantly.
Genetic Testing
Genetic testing plays a limited role in Alzheimer’s diagnosis. The gene most commonly associated with the disease, APOE-e4, increases risk but does not determine whether someone will develop the condition. Most experts do not routinely test for it, and results cannot fully predict who will get Alzheimer’s. Carrying one or even two copies of APOE-e4 is not a diagnosis.
The exception is early-onset Alzheimer’s, which strikes before age 65 and sometimes runs in families with a clear inheritance pattern. In those cases, genetic testing for rare mutations can be genuinely diagnostic and may also help family members understand their own risk.
How These Tests Work Together
Modern diagnostic guidelines define Alzheimer’s as a biological disease, not just a clinical syndrome. Researchers use a framework called A/T/N, where “A” stands for amyloid status, “T” for tau status, and “N” for neurodegeneration. Each letter can be assessed through different methods: amyloid through PET or spinal fluid, tau through PET or spinal fluid, and neurodegeneration through MRI or glucose PET. The more categories that come back positive, the more certain the diagnosis.
In practice, not every patient gets every test. A typical evaluation starts with cognitive screening and blood work, adds brain imaging if results point toward dementia, and may include spinal fluid analysis or specialized PET scans when the picture remains unclear. The process can take several weeks to several months, depending on specialist availability and how quickly symptoms are progressing. Doctors often repeat cognitive testing over time because the rate of change is itself a powerful diagnostic clue. Someone whose scores drop noticeably between visits six months apart is telling a very different story than someone whose scores remain stable.